Nanomedicine-mediated drug delivery for potential treatment of inflammatory bowel disease: a narrative review

Nanomedicine (Lond). 2024 Jan;19(2):163-179. doi: 10.2217/nnm-2023-0267. Epub 2024 Jan 29.

Abstract

Background & aims: Inflammatory bowel disease (IBD) is a condition characterized by chronic inflammation of the gastrointestinal tract, manifesting as either Crohn's disease (CrD) or ulcerative colitis (UC). Current treatment options for CrD and UC primarily focus on symptom management. In recent years, advancements in nanotechnology have increased the clinical applicability of nanoparticles (NPs) in treating IBD. This review explores the current research on NP-mediated drug-delivery systems for IBD treatment and assesses its advantages and limitations. Results: The authors examine diverse nanomedicine applications for IBD and address the current challenges and prospects in the field to advance nanomediated therapies in the future. Conclusion: Innovative NP-based treatment strategies promise a reliable and effective approach to IBD management.

Keywords: inflammatory bowel disease; nanomedicine; nanoparticles.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colitis, Ulcerative* / therapy
  • Crohn Disease* / diagnosis
  • Crohn Disease* / drug therapy
  • Drug Delivery Systems
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Nanomedicine